New Zealand’s a2 Milk is planning on listing on the Australian Securities Exchange.
The move, which was announced at the company’s general meeting on Tuesday, would see the company achieve a dual-listing, and potentially boost the liquidity of its shares.
The company said that it has already commenced the application process for an ASX listing, which it hopes to have completed with the first quarter of 2015, SMH reports.
"With a significant part of our earnings and growth coming from Australia, seeking an ASX listing is a logical strategic move for the company," Geoffrey Babbage a2’s managing director said.
"Listing on ASX will enable more Australian investors to participate in the company's growth and will increase the attractiveness and liquidity of its shares. The board believes that this will benefit all shareholders."
a2, who is being advised by Goldman Sachs and DLA Piper, said that no new capital will be raised in the listing and that the company will remain incorporated in New Zealand.
The popularity of a2 Milk has been increasing rapidly over the last number of years due to reports that the a2 beta-casein protein is easier to digest than A1 – a view that has often been shunned as scientifically unfounded.
Earlier this year, Curtin University received funding from the a2 Milk Company to conduct a pilot study into the digestive benefits of a2 milk, and found that subjects on a diet of a2 milk reported less bloating and abdominal pain than those consuming A1 milk.